MedTrace Logo

Biomed 101 and Interleukin-2 in Treating Patients With Kidney Cancer

NCT00004890 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2013-03-26

No results posted yet for this study

Summary

RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill kidney cancer cells. Biomed 101 may protect normal cells from the side effects of interleukin-2.

PURPOSE: Phase I trial to study the effectiveness of Biomed 101 in treating patients receiving interleukin-2 for kidney cancer.

Conditions

Interventions

BIOLOGICAL

aldesleukin

DRUG

Biomed 101

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • BioMedicines

    lead INDUSTRY

Principal Investigators

  • Robert A. Figlin, MD, FACP · Jonsson Comprehensive Cancer Center

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-12-31
Primary Completion
2002-12-31
Completion
2002-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004890 on ClinicalTrials.gov